Johnson & Johnson reports early-stage trial success for prostate cancer drug JNJ‑6143
Johnson & Johnson presented data from a phase‑1/2 study of its oral prostate cancer candidate JNJ‑6143 in 31 heavily pre‑treated patients. Seventy‑seven percent achieved PSA reductions of at least 50%, with 48% dropping 90% or more, and 69% of those with measurable tumors showed a confirmed complete or partial response. The drug, acquired through Halda Therapeutics’ purchase, displayed a manageable safety profile, prompting the launch of a phase‑2 trial enrolling about 100 patients.
Why it matters
The company says the results validate the RIPTAC platform and justify advancing JNJ‑6143 into a larger phase‑2 study, potentially expanding J&J’s oncology pipeline and future revenue streams.
Key facts
- 1The trial enrolled 31 evaluable patients receiving a 50 mg dose of JNJ‑6143. investing.com
- 2Seventy‑seven percent of patients had PSA reductions of at least 50%. investing.com
- 3Forty‑eight percent of patients had PSA reductions of at least 90%. investing.com
- 4Sixty‑nine percent of patients with measurable tumors achieved a confirmed complete or partial response. investing.com
- 5Less than 60% of patients experienced any treatment‑related adverse event; 10% experienced a serious (Grade 3 or higher) adverse event. pharmaphorum.com
- 6One patient discontinued treatment due to adverse effects. pharmaphorum.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.